Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy
Sign Up to like & getrecommendations! Published in 2018 at "Archives of Gynecology and Obstetrics"
DOI: 10.1007/s00404-018-4791-8
Abstract: PurposeEarly onset preeclampsia (PPE) contributes to life-threatening maternal complications and fetal demise. Pharmacogenomics is a precision medicine, and metabolizing enzymes responsive to antihypertensive remains understudied. The aim of this study was to evaluate the associations… read more here.
Keywords: cyp2d6 cyp2c9; associations polymorphisms; labetalol; cyp2d6 gene ... See more keywords
Treatment of Post-Coarctectomy Hypertension With Labetalol—A 9-Year Single-Center Experience
Sign Up to like & getrecommendations! Published in 2022 at "World Journal for Pediatric & Congenital Heart Surgery"
DOI: 10.1177/21501351221111797
Abstract: Background Although considering the pathophysiology of post-coarctectomy hypertension, β-blockers should be effective, experience with labetalol for treatment is limited in the literature. Methods Retrospective collection and analysis of data in children aged ≤6 years following… read more here.
Keywords: labetalol; coarctectomy; coarctectomy hypertension; treatment ... See more keywords
Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol-induced cholestasis
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1116422
Abstract: Labetalol is used for the therapy of hypertension in preeclampsia. Preeclampsia is characterized by high soluble endoglin (sEng) concentration in plasma and coincides with intrahepatic cholestasis during pregnancy (ICP), which threatens the fetus with the… read more here.
Keywords: labetalol; seng; plasma; mice ... See more keywords